Entero Therapeutics Files 8-K
Ticker: GRDX · Form: 8-K · Filed: Jul 31, 2024 · CIK: 1604191
| Field | Detail |
|---|---|
| Company | Entero Therapeutics, Inc. (GRDX) |
| Form Type | 8-K |
| Filed Date | Jul 31, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Disclosure
TL;DR
Entero Therapeutics filed an 8-K on 7/31/24. Check for updates.
AI Summary
Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) filed an 8-K on July 31, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorporated in Delaware, is in the Pharmaceutical Preparations industry and has its principal business address in Boca Raton, Florida.
Why It Matters
This filing indicates Entero Therapeutics is making required disclosures to the SEC, which could include significant business updates or financial information relevant to investors.
Risk Assessment
Risk Level: medium — 8-K filings can contain material information, but without specific details on the content, the risk level is moderate.
Key Numbers
- 001-37853 — SEC File Number (Identifies the company's filing history with the SEC.)
- 46-4993860 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Entero Therapeutics, Inc. (company) — Registrant
- First Wave BioPharma, Inc. (company) — Former Company Name
- AzurRx BioPharma, Inc. (company) — Former Company Name
- BioPharma d'Azur, Inc. (company) — Former Company Name
- July 31, 2024 (date) — Filing Date
- Boca Raton, Florida (location) — Business Address
FAQ
What specific information is being disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in this header information.
What are the key exhibits included with this 8-K filing?
The filing states 'Financial Statements and Exhibits' are included, but the specific list of exhibits is not detailed in the provided text.
When was the company formerly known as First Wave BioPharma, Inc.?
The date of the name change from First Wave BioPharma, Inc. to Entero Therapeutics, Inc. was September 21, 2021.
What is the company's primary industry classification?
Entero Therapeutics, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS' with SIC code 2834.
Where is Entero Therapeutics, Inc. headquartered?
The company's business address is located at 777 Yamato Road, Suite 502, Boca Raton, Florida, 33431.
Filing Stats: 550 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2024-07-31 10:54:33
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ENTO Nasdaq Capital Mark
Filing Documents
- tm2420546d1_8k.htm (8-K) — 27KB
- tm2420546d1_ex99-1.htm (EX-99.1) — 14KB
- tm2420546d1_ex99-1img001.jpg (GRAPHIC) — 10KB
- 0001104659-24-084206.txt ( ) — 230KB
- fwbi-20240731.xsd (EX-101.SCH) — 3KB
- fwbi-20240731_lab.xml (EX-101.LAB) — 33KB
- fwbi-20240731_pre.xml (EX-101.PRE) — 22KB
- tm2420546d1_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On July 31, 2024, Entero Therapeutics, Inc., a Delaware corporation (the "Company") issued a press release announcing the issuance of a letter to stockholders from its Chief Executive Officer, James Sapirstein (the "Press Release"). The Press Release is attached hereto as Exhibit 99.1 and is being furnished herewith. The information in this Item 7.01 of this Current Report on Form 8-K (the "Current Report") and the Press Release being furnished herewith shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise in this Item 7.01 and in the Press Release attached as Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. 99.1* Press Release, dated July 31, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Furnished herewith
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entero Therapeutics, Inc. July 31, 2024 By: /s/ James Sapirstein Name: James Sapirstein Title: Chief Executive Officer